IDEXX Laboratories Announces Fourth Quarter Results and Full Year Results
Organic revenue growth excludes the impact of changes in currency exchange rates, which contributed approximately 5% to revenue growth, and revenue from businesses acquired or divested subsequent to the beginning of the prior year period, which had minimal impact on revenue growth.
"IDEXX had a strong fourth quarter that exceeded our expectations," stated Jonathan W. Ayers, Chairman and Chief Executive Officer. "Organic revenue growth, led by our Companion Animal Group, increased modestly to 6%, as strong demand for certain products such as our Catalyst Dx® chemistry analyzer offset continued economic weakness and soft consumer spending."
"Sales of instruments and consumables, our largest business, benefited from Catalyst sales as we placed 763 units in the fourth quarter and 2,046 units for the year."
"International markets, particularly the Asia Pacific region, continued to perform very well. In that region, organic growth was 30% for the quarter and 20% for the year, reflecting a further acceleration of growth in this region."
"Throughout the year, we continued to identify opportunities for increased operating efficiency while maintaining investment in areas critical to achieving our longer-term strategic and operational objectives. This focus on operational efficiency enabled us to exceed our earnings guidance for the year, despite weaker than anticipated top-line growth."
"As we look to 2010, we remain confident in our growth strategies due to the fundamental attractiveness of our markets, our unique and innovative product and service offering, and our global footprint. We also are targeting earnings to grow faster than revenue, reflecting operating margin expansion in our two largest businesses, instruments and consumables and reference laboratory services."
Revenue Performance
Please refer to the table below entitled "Revenues and Revenue Growth Analysis by Product and Service Categories" in conjunction with the following discussion.
Companion Animal Group. Companion Animal Group ("CAG") revenues for the fourth quarter of 2009 were $217.9 million compared to $196.5 million for the fourth quarter of 2008. Changes in foreign currency exchange rates and revenues from a recently acquired business contributed approximately 4% and 1%, respectively, to revenue growth. Organic growth of 6% was the result of increased sales volume, primarily in the IDEXX VetLab® and laboratory and consulting services product lines. In the IDEXX VetLab® product line, higher sales volume was driven by sales of our Catalyst Dx® chemistry analyzer and instrument consumables. In the laboratory and consulting services product line, revenue growth was due to higher volume and higher unit sales prices on reference laboratory tests. These favorable impacts were partly offset by lower sales volume and lower average unit sales prices for LaserCyte® hematology analyzers.
Water. Water segment revenues for the fourth quarter of 2009 were $18.5 million compared to $17.2 million for the fourth quarter of 2008. Changes in foreign currency exchange rates contributed approximately 5% to revenue growth. Organic revenue growth of 3% was the result of higher unit sales prices due, in part, to higher relative sales in geographies where products are sold at higher unit sales prices.
Production Animal Segment. Production Animal Segment ("PAS") revenues for the fourth quarter of 2009 were $23.4 million compared to $20.3 million for the fourth quarter of 2008. Changes in foreign currency exchange rates contributed approximately 10% to revenue growth. Organic revenue growth of 5% was the result of higher sales volumes, partly offset by lower unit sales prices.
Year-to-Date Results
Revenues for the year ended December 31, 2009 increased 1% to $1.032 billion, from $1.024 billion for the year ended December 31, 2008. Organic growth for the year ended December 31, 2009, was 5%. Changes in currency exchange rates and the impact of divestitures and discontinued products, net of revenues from businesses recently acquired, reduced revenue growth by approximately 4%.
EPS for 2009 were $2.01, compared to $1.87 for the year ended December 31, 2008. EPS grew 6% when compared to 2008 non-GAAP diluted EPS of $1.90. Please refer to the non-GAAP financial measures table below.
Additional Operating Results for the Fourth Quarter
Gross profit for the fourth quarter of 2009 increased $12.4 million, or 10%, to $132.9 million from $120.5 million for the fourth quarter of 2008. As a percentage of total revenue, gross profit decreased slightly to 49%. The decrease in gross profit percentage was due primarily to the unfavorable net impact of foreign currency exchange rates, as the favorable impact on revenue of changes in foreign currency exchange rates was more than offset by losses on foreign currency hedge contracts and by the unfavorable impact on foreign currency denominated expenses. Gross profit percentage was also impacted by higher relative sales of lower margin IDEXX VetLab® instruments and laboratory and consulting services and lower average sales prices in certain product lines. These unfavorable items were partly offset by gross profit improvement in our laboratory and consulting services product line, lower royalty expense, and lower depreciation expense associated with IDEXX VetLab® instruments that are under rental agreements with customers.
Research and development ("R&D") expense for the fourth quarter of 2009 was $16.0 million, or 6% of revenue, compared to $17.1 million, or 7% of revenue for the fourth quarter of 2008. The decrease in R&D expense was due to the absence of pharmaceutical business R&D spending in the fourth quarter of 2009, resulting from the disposition of substantially all of our pharmaceutical product line and assets in the fourth quarter of 2008.
Selling, general and administrative ("SG&A") expense for the fourth quarter of 2009 was $72.8 million, or 27% of revenue, compared to $66.1 million, or 27% of revenue, for the fourth quarter of 2008. The increase in SG&A expense resulted primarily from higher personnel costs in selling, customer support and administrative functions, and the unfavorable impact of exchange rate changes on foreign currency denominated expenses. Fourth quarter 2008 SG&A included a charge of $1.5 million related to the 2008 disposition and the related restructuring of the remaining pharmaceutical product line.
Supplementary Analysis of Results
The accompanying financial tables provide more information concerning our revenue and other operating results for the three and twelve months ended December 31, 2009, as well as a reconciliation of earnings per share to non-GAAP EPS.
Outlook for 2010
The Company provides the following updated guidance for the full year of 2010. This guidance reflects an assumption that the value of the U.S. dollar relative to other currencies will remain at its current level for the balance of 2010. Fluctuations in foreign currency exchange rates from current levels could have a significant positive or negative impact on our actual results of operations in 2010.
- Revenues are expected to be $1.1 to $1.115 billion, which represents reported revenue growth of 7% to 8% and organic revenue growth of 5% to 6%. This guidance is higher than the previous guidance of $1.08 to $1.1 billion, provided in October 2009, as a slight increase in anticipated organic revenue growth is anticipated to be partially offset by lower estimated currency benefits from the weakening of the U.S. Dollar relative to other major currencies.
- EPS are expected to be $2.20 to $2.25, compared to our previous guidance of $2.15 to $2.25.
- Free cash flow is expected to be approximately 110% of net income.
Conference Call and Webcast Information
IDEXX Laboratories will be hosting a conference call today at 9:00 a.m. (eastern) to discuss its fourth quarter results. To participate in the conference call, dial 1-612-288-0329 or 1-800-288-8967 and reference confirmation code 143973. An audio replay will be available through February 5, 2010 by dialing 1-320-365-3844 and referencing replay code 143973.
The call will also be available via live or archived Webcast on the IDEXX Laboratories' web site at www.idexx.com.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,800 people and offers products to customers in over 100 countries.
Note Regarding Forward-Looking Statements
This press release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the impact of a weak economy on demand for the Company's products and services; the impact of changes and disruptions in financial and currency markets; the effectiveness of the Company's sales and marketing activities; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition, technological change, and veterinary hospital consolidation on the markets for the Company's products; the Company's ability to manufacture complex biologic products; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; the effects of interruptions to the Company's operations due to natural disasters or system failures; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (PDF), and quarterly report on Form 10-Q for the quarter ended September 30, 2009 (PDF), in the section captioned "Risk Factors."
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||
| Consolidated Statement of Operations | |||||||
| Amounts in thousands except per share data (Unaudited) | |||||||
| Three Months Ended | Twelve Months Ended | ||||||
| December 31, | December 31, | December 31, | December 31, | ||||
| 2009 | 2008 | 2009 | 2008 | ||||
| Revenue: | Revenue | $270,335 | $243,293 | $1,031,633 | $1,024,030 | ||
| Expenses | |||||||
| and Income: | Cost of revenue | 137,404 | 122,772 | 505,352 | 494,264 | ||
| Gross profit | 132,931 | 120,521 | 526,281 | 529,766 | |||
| Sales and marketing | 43,383 | 39,951 | 167,748 | 169,693 | |||
| General and administrative | 29,393 | 26,179 | 117,440 | 115,586 | |||
| Research and development | 16,008 | 17,063 | 65,124 | 70,552 | |||
| Loss on disposition of pharmaceutical product lines and related restructuring | – | 1,479 | – | 1,479 | |||
| Income from operations | 44,147 | 35,849 | 175,969 | 172,456 | |||
| Interest expense, net | (243) | (581) | (1,430) | (2,269) | |||
| Income before provision for income taxes | 43,904 | 35,268 | 174,539 | 170,187 | |||
| Provision for income taxes | 12,943 | 11,713 | 52,304 | 54,018 | |||
| Net Income: | Net income | 30,961 | 23,555 | 122,235 | 116,169 | ||
| Less: Noncontrolling interest in subsidiary's earnings | 10 | – | 10 | – | |||
| Net income attributable to stockholders | $30,951 | $23,555 | $122,225 | $116,169 | |||
| Earnings per share: Basic | $0.53 | $0.40 | $2.08 | $1.94 | |||
| Earnings per share: Diluted | $0.51 | $0.39 | $2.01 | $1.87 | |||
| Shares outstanding: Basic | 58,506 | 59,453 | 58,809 | 59,953 | |||
| Shares outstanding: Diluted | 60,507 | 61,083 | 60,682 | 62,249 | |||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||
| Key Operating Information (Unaudited) | |||||||
| Three Months Ended | Twelve Months Ended | ||||||
| December 31, | December 31, | December 31, | December 31, | ||||
| 2009 | 2008 | 2009 | 2008 | ||||
| Key Operating | Gross profit | 49.2% | 49.5% | 51.0% | 51.7% | ||
| Ratios (as a | Sales, marketing, general and | ||||||
| percentage of | administrative expense | 26.9% | 27.2% | 27.6% | 27.9% | ||
| revenue): | Research and development expense | 5.9% | 7.0% | 6.3% | 6.9% | ||
| Loss on disposition of pharmaceutical product lines and related restructuring | – | 0.6% | – | 0.1% | |||
| Income from operations(1) | 16.3% | 14.7% | 17.1% | 16.8% | |||
| |||||||
| International Revenue: | International revenue (in thousands) | $118,660 | $97,071 | $417,116 | $413,973 | ||
| International revenue as a percentage of total revenue | 43.9% | 39.9% | 40.4% | 40.4% | |||
(1) The sum of individual items may not equal the total due to rounding. | |||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||||
| Non-GAAP Financial Measures | |||||||||||
| Amounts in thousands except per share data (Unaudited) | |||||||||||
| Three Months Ended | |||||||||||
Gross Profit | Income from Operations | Net Income Attributable to Stockholders | Earnings per Share Diluted | ||||||||
| Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | ||||
| 2009 | 2008 | 2009 | 2008 | 2009 | 2008 | 2009 | 2008 | ||||
| GAAP measurement | $132,931 | $120,521 | $44,147 | $35,849 | $30,951 | $23,555 | $0.51 | $0.39 | |||
| % of revenue | 49.2% | 49.5% | 16.3% | 14.7% | 11.4% | 9.7% | |||||
| Disposition of pharmaceutical product lines and restructuring(1) | – | – | – | 1,479 | – | 3,598 | – | 0.06 | |||
| Non-GAAP comparative measurements(2) | $132,931 | $120,521 | $44,147 | $37,328 | $30,951 | $27,153 | $0.51 | $0.44 | |||
| % of revenue | 49.2% | 49.5% | 16.3% | 15.3% | 11.4% | 11.2% | |||||
Management believes adjusted diluted EPS is a useful non-GAAP financial measure to evaluate the results of ongoing operations, excluding significant specified events, period over period, and therefore believes that investors may find this information useful in addition to the GAAP results.
We use these supplemental non-GAAP financial measures to evaluate the Company's comparative financial performance. The specified items that are excluded in these non-GAAP measures are actual charges that impact net income and cash flows, however, we believe that it is useful to evaluate our core business performance period over period excluding these specified items, in addition to relying upon GAAP financial measures.
(1)We believe that impact of the disposition of certain pharmaceutical product lines and the related restructuring of the remaining pharmaceutical business in 2008 is not indicative of future performance because significant transactions and related costs of a similar nature are not likely to recur within a reasonable period. In the fourth quarter of 2008 we completed a transaction to sell our ACAREXX and SURPASS pharmaceutical products and a product then under development, which were a part of our CAG segment, and subsequently restructured the remaining pharmaceutical business.
(2)The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation. | |||||||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||||
| Non-GAAP Financial Measures | |||||||||||
| Amounts in thousands except per share data (Unaudited) | |||||||||||
| Twelve Months Ended | |||||||||||
Gross Profit | Income from Operations | Net Income Attributable to Stockholders | Earnings per Share Diluted | ||||||||
| Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | Dec. 31, | ||||
| 2009 | 2008 | 2009 | 2008 | 2009 | 2008 | 2009 | 2008 | ||||
| GAAP measurement | $526,281 | $529,766 | $175,969 | $172,456 | $122,225 | $116,169 | $2.01 | $1.87 | |||
| % of revenue | 51.0% | 51.7% | 17.1% | 16.8% | 11.8% | 11.3% | |||||
| Disposition of pharmaceutical product lines and restructuring(1) | – | – | – | 1,479 | – | 3,598 | – | 0.06 | |||
| Discrete income tax benefits(2) | – | – | – | – | – | (1,472) | – | (0.02) | |||
| Non-GAAP comparative measurements (2) | $526,281 | $529,766 | $175,969 | $173,935 | $122,225 | $118,295 | $2.01 | $1.90 | |||
| % of revenue | 51.0% | 51.7% | 17.1% | 17.0% | 11.8% | 11.6% | |||||
Management believes adjusted diluted EPS is a useful non-GAAP financial measure to evaluate the results of ongoing operations, excluding significant specified events, period over period, and therefore believes that investors may find this information useful in addition to the GAAP results.
We use these supplemental non-GAAP financial measures to evaluate the Company's comparative financial performance. The specified items that are excluded in these non-GAAP measures are actual charges that impact net income and cash flows; however, we believe that it is useful to evaluate our core business performance period over period excluding these specified items, in addition to relying upon GAAP financial measures.
(1)We believe that the impact of the disposition of certain pharmaceutical product lines and the related restructuring of the remaining pharmaceutical business in the fourth quarter of 2008 is not indicative of future performance because significant transactions and related costs of a similar nature are not likely to recur within a reasonable period. In the fourth quarter of 2008 we completed a transaction to sell our ACAREXX and SURPASS pharmaceutical products and a product then under development, which were a part of our CAG segment, and subsequently restructured the remaining pharmaceutical business.
(2)We believe that certain significant discrete income tax items create impacts on financial measures that are not indicative of future performance because the items are not likely to recur within a reasonable period. For 2008, the separately identified discrete income tax benefit was due to a reduction in international deferred tax liabilities due to lower anticipated international tax rates.
(3)The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation. | |||||||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||
| Segment Information | |||||||
| Amounts in thousands (Unaudited) | |||||||
| Three Months Ended | Twelve Months Ended | ||||||
| December 31, | December 31, | December 31, | December 31, | ||||
| 2009 | 2008 | 2009 | 2008 | ||||
| Revenue: | CAG | $217,861 | $196,523 | $843,303 | $834,056 | ||
| Water | 18,507 | 17,182 | 73,214 | 74,469 | |||
| PAS | 23,360 | 20,310 | 77,208 | 80,762 | |||
| Other | 10,607 | 9,278 | 37,908 | 34,743 | |||
| Total | $270,335 | $243,293 | $1,031,633 | $1,024,030 | |||
| Gross Profit: | CAG | $100,346 | $90,359 | $410,356 | $412,199 | ||
| Water | 11,272 | 11,479 | 47,233 | 47,052 | |||
| PAS | 15,592 | 14,307 | 51,256 | 55,005 | |||
| Other | 5,605 | 4,289 | 17,067 | 15,131 | |||
| Unallocated | 116 | 87 | 369 | 379 | |||
| Total | $132,931 | $120,521 | $526,281 | $529,766 | |||
| Income from | |||||||
| Operations: | CAG | $29,304 | $24,210 | $136,121 | $129,620 | ||
| Water | 7,279 | 7,893 | 31,615 | 31,330 | |||
| PAS | 6,269 | 6,936 | 17,271 | 21,760 | |||
| Other | 3,570 | 919 | 3,425 | 1,555 | |||
| Unallocated | (2,275) | (4,109) | (12,463) | (11,809) | |||
| Total | $44,147 | $35,849 | $175,969 | $172,456 | |||
| Gross Profit | CAG | 46.1% | 46.0% | 48.7% | 49.4% | ||
| (as a | Water | 60.9% | 66.8% | 64.5% | 63.2% | ||
| percentage | PAS | 66.7% | 70.4% | 66.4% | 68.1% | ||
| of revenue): | Other | 52.8% | 46.2% | 45.0% | 43.6% | ||
| Income from | |||||||
| Operations | CAG | 13.5% | 12.3% | 16.1% | 15.5% | ||
| (as a | Water | 39.3% | 45.9% | 43.2% | 42.1% | ||
| percentage | PAS | 26.8% | 34.2% | 22.4% | 26.9% | ||
| of revenue): | Other | 33.7% | 9.9% | 9.0% | 4.5% | ||
| IDEXX Laboratories, Inc. and Subsidiaries | ||||||||
| Revenues and Revenue Growth Analysis by Product and Service Categories | ||||||||
| Amounts in thousands (Unaudited) | ||||||||
| Three Months Ended | ||||||||
Net Revenue | December 31, 2009 | December 31, 2008 | Dollar Change | Percentage Change | Percentage Change from Currency(1) | Percentage Change from Acquisitions/ Divestitures(2) | Percentage Change Net of Acquisitions/ Divestitures and Currency Effect(3) | |
| CAG | $217,861 | $196.523 | $21,338 | 10.9% | 4.3% | 0.5% | 6.1% | |
| Water | 18,507 | 17,182 | 1,325 | 7.7% | 4.7% | – | 3.0% | |
| PAS | 23,360 | 20,310 | 3,050 | 15.0% | 9.6% | – | 5.4% | |
| Other | 10,607 | 9,278 | 1,329 | 14.3% | 2.6% | – | 11.7% | |
| Total | $270,335 | $243,293 | $27,042 | 11.1% | 4.7% | 0.4% | 6.0% | |
Three Months Ended | ||||||||
Net CAG Revenue | December 31, 2009 | December 31, 2008 | Dollar Change | Percentage Change | Percentage Change from Currency(1) | Percentage Change from Acquisitions/ Divestitures(2) | Percentage Change Net of Acquisitions/ Divestitures and Currency Effect(3) | |
| Instruments and consumables | $92,817 | $81,559 | $11,258 | 13.8% | 4.3% | – | 9.5% | |
| Rapid assay products | 30,081 | 30,240 | (159) | (0.5%) | 1.8% | – | (2.3%) | |
| Laboratory and consulting services | 75,423 | 65,260 | 10,163 | 15.6% | 6.1% | 2.1% | 7.4% | |
| Practice information management systems and digital radiography | 19,540 | 18,918 | 622 | 3.3% | 1.9% | 0.6% | 0.8% | |
| Pharmaceutical products | – | 546 | (546) | (100.0%) | – | (100.0%) | – | |
| Net CAG revenue | $217,861 | $196,523 | $21,338 | 10.9% | 4.3% | 0.5% | 6.1% | |
(1)Represents the percentage change in revenue attributed to the effect of changes in currency rates from the three months ended December 31, 2008 to the three months ended December 31, 2009.
(2)Represents the percentage change in revenue during the three months ended December 31, 2009 compared to the three months ended December 31, 2008 attributed to incremental revenues from businesses acquired or revenues lost from businesses divested or discontinued subsequent to September 30, 2008.
(3)Organic growth
| IDEXX Laboratories, Inc. and Subsidiaries | ||||||||
| Revenues and Revenue Growth Analysis by Product and Service Categories | ||||||||
| Amounts in thousands (Unaudited) | ||||||||
| Twelve Months Ended | ||||||||
Net Revenue | December 31, 2009 | December 31, 2008 | Dollar Change | Percentage Change | Percentage Change from Currency(1) | Percentage Change from Acquisitions/ Divestitures(2) | Percentage Change Net of Acquisitions/ Divestitures and Currency Effect(3) | |
| CAG | $843,303 | $834,056 | $9,247 | 1.1% | (2.3%) | (2.0%) | 5.4% | |
| Water | 73,214 | 74,469 | (1,255) | (1.7%) | (3.4%) | – | 1.7% | |
| PAS | 77,208 | 80,762 | (3,554) | (4.4%) | (3.4%) | – | (1.0%) | |
| Other | 37,908 | 34,743 | 3,165 | 9.1% | (0.4%) | – | 9.5% | |
| Total | $1,031,633 | $1,024,030 | $7,603 | 0.7% | (2.4%) | (1.6%) | 4.7% | |
Twelve Months Ended | ||||||||
Net CAG Revenue | December 31, 2009 | December 31, 2008 | Dollar Change | Percentage Change | Percentage Change from Currency(1) | Percentage Change from Acquisitions/ Divestitures(2) | Percentage Change Net of Acquisitions/ Divestitures and Currency Effect(3) | |
| Instruments and consumables | $332,706 | $318,533 | $14,173 | 4.4% | (2.7%) | – | 7.1% | |
| Rapid assay products | 147,078 | 146,867 | 211 | 0.1% | (0.7%) | – | 0.8% | |
| Laboratory and consulting services | 298,410 | 288,244 | 10,166 | 3.5% | (3.0%) | 0.7% | 5.8% | |
| Practice information management systems and digital radiography | 65,055 | 61,291 | 3,764 | 6.1% | (0.8%) | 0.2% | 6.7% | |
| Pharmaceutical products | 54 | 19,121 | (19,067) | (99.7%) | – | (99.6%) | (0.1%) | |
| Net CAG revenue | $843,303 | $834,056 | $9,247 | 1.1% | (2.3%) | (2.0%) | 5.4% | |
(1)Represents the percentage change in revenue attributed to the effect of changes in currency rates from the twelve months ended December 31, 2008 to the twelve months ended December 31, 2009.
(2)Represents the percentage change in revenue during the twelve months ended December 31, 2009 compared to the twelve months ended December 31, 2008 attributed to incremental revenues from businesses acquired or revenues lost from businesses divested or discontinued subsequent to December 31, 2007.
(3)Organic growth
| IDEXX Laboratories, Inc. and Subsidiaries | |||
| Consolidated Balance Sheet | |||
| Amounts in thousands (Unaudited) | |||
| December 31, 2009 | Deccember 31, 2008 | ||
| Assets: | Current Assets: | ||
| Cash and cash equivalents | $106,728 | $78,868 | |
| Accounts receivable, net | 115,107 | 111,498 | |
| Inventories | 110,425 | 115,926 | |
| Other current assets | 44,078 | 49,598 | |
| Total current assets | 376,338 | 355,890 | |
| Property and equipment, at cost | 346,592 | 320,198 | |
| Less: accumulated depreciation | 146,646 | 130,552 | |
| Property and equipment, net | 199,946 | 189,646 | |
| Other long-term assets, net | 232,243 | 219,901 | |
| Total assets | $808,527 | $765,437 | |
| Liabilities and | |||
| Stockholders’ | |||
| Equity: | Current Liabilities: | ||
| Accounts payable | $19,133 | $28,006 | |
| Accrued expenses | 104,959 | 104,616 | |
| Debt | 119,603 | 151,385 | |
| Deferred revenue | 12,610 | 11,285 | |
| Total current liabilities | 256,305 | 295,292 | |
| Long-term debt, net of current portion | 4,281 | 5,094 | |
| Other long-term liabilities | 33,362 | 26,857 | |
| Total long-term liabilities | 37,643 | 31,951 | |
Total stockholders’ equity | 514,569 | 438,194 | |
| Noncontrolling interest | 10 | – | |
| Total equity | $514,579 | $438,194 | |
| Total liabilities and stockholders’ equity | $808,527 | $765,437 | |
| IDEXX Laboratories, Inc. and Subsidiaries | ||||||
| Key Balance Sheet Information (Unaudited) | ||||||
| December 31, 2009 | September 30, 2009 | June 30, 2009 | March 31, 2009 | December 31, 2009, | ||
| Key | ||||||
| Balance Sheet | Days sales outstanding | 38.9 | 41.2 | 40.2 | 43.8 | 41.9 |
| Information: | Inventory turns | 2.2 | 1.8 | 1.8 | 1.6 | 2.0 |
| IDEXX Laboratories, Inc. and Subsidiaries | |||||
| Consolidated Statement of Cash Flows | |||||
| Amounts in thousands (Unaudited) | |||||
| Twelve Months Ended | |||||
| December 31, 2009 | December 31, 2008 | ||||
| Operating: | Cash Flows from Operating Activities: | ||||
| Net income attributable to stockholders | $122,225 | $116,169 | |||
| Noncontrolling interest in subsidiary's earnings | 10 | – | |||
| Net income | 122,235 | 116,169 | |||
| Non-cash charges | 63,042 | 60,650 | |||
| Changes in current assets and liabilities, net of acquisitions and disposals | (11,559) | (33,511) | |||
| Net cash used by operating activities | $173,718 | $143,308 | |||
| Investing: | Cash Flows from Investing Activities: | ||||
| Purchase of property and equipment | (49,418) | (89,237) | |||
| Proceeds from disposition of pharmaceutical product lines | 3,377 | 7,025 | |||
| Proceeds from sale of property and equipment | 2,079 | – | |||
| Acquisitions of intangible assets and business, net of cash acquired | (7,180) | (8,649) | |||
| Acquisitions of equipment leased to customers | (1,245) | (734) | |||
| Net cash used by investing activities | $(52,387) | $(91,595) | |||
| Financing: | Cash Flows from Financing Activities: | ||||
| Borrowings (payments) on revolving credit facilities, net | (32,830) | 79,550 | |||
| Payment of other notes payable | (926) | (595) | |||
| Purchase of treasury stock | (83,099) | (132,342) | |||
| Proceeds from the exercise of stock options and employee stock purchase plans | 16,366 | 16,360 | |||
| Tax benefit from exercise of stock options and vesting of restricted stock units | 5,194 | 6,237 | |||
| Net cash used by financing activities | $(95,295) | $(30,790) | |||
| Net effect of changes in exchange rates on cash | 1,824 | (2,415) | |||
| Net increase in cash and cash equivalents | 27,860 | 18,508 | |||
| Cash and cash equivalents, beginning of period | 78,868 | 60,360 | |||
| Cash and cash equivalents, end of period | $106,728 | $78,868 | |||
| IDEXX Laboratories, Inc. and Subsidiaries | |||
| Free Cash Flow | |||
| Amounts in thousands (Unaudited) | |||
| Twelve Months Ended | |||
| December 31, 2009 | December 31, 2008 | ||
| Free Cash | |||
| Flow: | Net cash provided by operating activities | $173,718 | $143,308 |
| Financing cash flows attributable to tax benefits from exercise of stock options and vesting of restricted stock units | 5,194 | 6,237 | |
| Purchase of property and equipment | (49,418) | (89,237) | |
| Acquisition of equipment leased to customers | (1,245) | (734) | |
| Free cash flow | $128,249 | $59,574 | |
Free cash flow indicates the cash generated from operations and tax benefits attributable to stock option exercises, reduced by investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business. We believe this is a common financial measure useful to further evaluate the results of operations. | |||
| IDEXX Laboratories, Inc. and Subsidiaries | |
| Cash Flow Impact of Pharmaceutical Transactions and Restructuring | |
| Amounts in thousands (Unaudited) | |
| December 31, 2008 | |
| Proceeds | $8,402 |
| Restructuring and transaction expenses incurred | (671) |
| Tax charge related to disposal of nondeductible goodwill | (2,666) |
| Realization of deferred tax assets | 4,228 |
| Tax benefit realized from transaction loss | 401 |
| Net cash flow realized from transaction and restructuring | $9,694 |
| IDEXX Laboratories, Inc. and Subsidiaries | ||||
| Common Stock Repurchases | ||||
| Amounts in thousands except per share data (Unaudited) | ||||
| Three Months Ended | Twelve Months Ended | |||
| December 31, 2009 | December 31, 2008 | December 31, 2009 | December 31, 2008 | |
| Share repurchases during the period | 486 | 297 | 1,919 | 2,640 |
| Average price paid per share | $51.69 | $33.41 | $43.30 | $50.14 |
Shares remaining under repurchase authorization as of December 31, 2009: | 2,294 | |||
Contact: Merilee Raines, Chief Financial Officer, (207) 556-8155